Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 11, 2018
Context: The filing serves as a Regulation FD disclosure to furnish investor presentations (Exhibits 99.1 and 99.2) intended for use at the BMO Prescriptions for Success Conference on December 12, 2018, and in other investor meetings. The company is designated as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report acts solely as a vehicle to distribute attached presentation materials and does not contain a financial statement or tabular data within the text body.
Material Changes
No material changes to financial performance or operations are detailed in the text of this filing. The document references the distribution of a "Business Update" and "Corporate Update" presentation but does not summarize the specific content or changes contained therein.
Guidance, Outlook, and Risks
Management Commentary: The filing explicitly states that the information is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 17 of the Exchange Act. Consequently, it is not subject to the liabilities of that section nor incorporated by reference in other filings.
Risks and Contingencies: No specific risks or contingencies are disclosed in the text of this report.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Business Update Investor Presentation) for specific operational and financial details.
- Review the attached Exhibit 99.2 (Corporate Update Investor Presentation) for strategic updates.
- Verify that the information in the presentations is not considered "filed" for liability purposes under Section 17 of the Exchange Act.
- Confirm the company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.